By author on

The FDA has given fast track status to Pyxis’ drug candidate, PYX-201. This means that the review and approval process for this drug will be accelerated because it shows promise in treating a serious condition. This kind of designation is often granted to drugs that could potentially fulfill an unmet medical need. While the specific condition PYX-201 aims to treat wasn’t mentioned, similar fast-tracked drugs in the past have included names like Keytruda for cancer and Trikafta for cystic fibrosis.

By author on

Regeneron is trying for a second time to get approval for its blood cancer treatment. If possible, could you include the names of some related medications in your explanation?

By author on

Astellas, a pharmaceutical company, disagrees with European authorities about their drug Izervay, which is meant to treat geographic atrophy, a type of eye disease.